Is AstraZeneca (AZN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.0% / 30% | 2.5% / 30% | 4.6% / 30% | 0.61% / 5% | ✓ HALAL |
| DJIM | 13.0% / 33% | 2.5% / 33% | 4.6% / 33% | 0.61% / 5% | ✓ HALAL |
| MSCI | 25.6% / 33% | 5.0% / 33% | 9.0% / 33% | 0.61% / 5% | ✓ HALAL |
| S&P | 13.0% / 33% | 2.5% / 33% | 4.6% / 33% | 0.61% / 5% | ✓ HALAL |
| FTSE | 25.6% / 33% | 5.0% / 33% | 9.0% / 50% | 0.61% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 81.7% | |
| Operating Margin | 21.6% | |
| Net Margin | 17.4% | |
| Return on Equity (ROE) | 22.8% | |
| Return on Assets (ROA) | 8.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $14.6B |
| Free Cash Flow | $8.7B |
| Total Debt | $29.1B |
| Debt-to-Equity | 61.0 |
| Current Ratio | 0.9 |
| Total Assets | $114.1B |
Price & Trading
| Last Close | GBp 13,830.00 |
| 50-Day MA | GBp 14,392.72 |
| 200-Day MA | GBp 12,789.67 |
| Avg Volume | 2.7M |
| Beta | 0.2 |
|
52-Week Range
GBp 9,573.50
| |
About AstraZeneca (AZN)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Purification Calculator
As a halal stock with 0.61% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AstraZeneca (AZN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AstraZeneca is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AstraZeneca's debt ratio?
AstraZeneca's debt ratio is 13.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 25.6%.
Does AstraZeneca require dividend purification?
Yes, AstraZeneca has an impermissible income ratio of 0.61%, which means 0.61% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are AstraZeneca's key financial metrics?
AstraZeneca has a market capitalization of $221.8B, trailing P/E ratio of 29.1, and revenue of $58.7B. The company maintains a gross margin of 81.7% and a net margin of 17.4%. Return on equity stands at 22.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.